8-K current report · filed Oct 29, 2026

West Pharmaceutical Services (WST) 8-K Current Report: October 29, 2026

Item EX-99.2Item EX-99.1Item 2.02Item 7.01WST overview

Short answer

West Pharmaceutical Services (WST) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Third-quarter 2026 financial results announced on October 29, 2026.

West Pharmaceutical Services 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Third-quarter 2026 financial results announced on October 29, 2026
  • Investor-relevant results, guidance and management commentary contained in Exhibit 99.1 press release

Item 7.01 · Regulation FD Disclosure

  • Investor presentation materials accompany the earnings disclosure as Exhibit 99.2
  • Presentation available through West Pharmaceutical Services’ investor-relations website
  • Materials provide supplemental context for the Item 2.02 financial results discussion

Item EX-99.1 · Exhibit EX-99.1

  • Q3 net sales $874.5M, up 8.7%, with organic growth 11.9%, signaling strong underlying demand
  • Adjusted EPS $2.66, up 35.7%, supported by operating margin expansion to 25.3% from 21.1%
  • HVP Components organic sales up 20.3% to $469.1M, offsetting West Vantage organic sales decline of 6.6%
  • Full-year sales guidance raised to $3.41B-$3.42B and adjusted EPS guidance to $9.38-$9.48
  • Share repurchases reached $685M year-to-date, while capital spending guidance fell to $215M-$220M from $250M-$275M

Item EX-99.2 · Exhibit EX-99.2

  • Q3 net sales $874.5M, up 8.7% reported and 11.9% organically, signaling strong underlying demand
  • Adjusted EPS $2.66, up 35.7%, with adjusted operating margin reaching 25.3%, up 420 basis points
  • Proprietary Products organic sales growth 16.6%, led by HVP Components up 20.3% and HVP Delivery Devices up 26.4%
  • West Vantage organic sales fell 6.6% following planned loss of a CGM customer, though margins improved sequentially
  • 2026 guidance maintained at $3.41B to $3.42B revenue and $9.38 to $9.48 adjusted EPS, with $215M to $220M capital expenditures

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other West Pharmaceutical Services 8-K filings

Get the next WST 8-K as it lands

Follow WST for push alerts, or ask the research agent what this filing means.